-transparent.png){kind=logo}
The effects of somatostatin on tolbutamide-stimulated insulin release were studied in 4 patients with insulin-producing tumors of the pancreas and in 6 normal subjects. In contrast to its effective inhibition of insulin release in normal subjects, somatostatin, without exception, failed to inhibit tolbutamide-induced insulin release in the patients with pancreatic beta-cell tumors. This differential effect of somatostatin may prove useful in the diagnosis of insulin-producing tumors of the pancreas.
Related Publications
M Lorenzi, and
J E Gerich, and
J H Karam, and
P H Forsham
January 1976,
The Netherlands journal of medicine,
M Lorenzi, and
J E Gerich, and
J H Karam, and
P H Forsham
January 1982,
Revista clinica espanola,
M Lorenzi, and
J E Gerich, and
J H Karam, and
P H Forsham
March 1977,
The Journal of endocrinology,
M Lorenzi, and
J E Gerich, and
J H Karam, and
P H Forsham
November 1977,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
M Lorenzi, and
J E Gerich, and
J H Karam, and
P H Forsham
January 2013,
American journal of physiology. Endocrinology and metabolism,
M Lorenzi, and
J E Gerich, and
J H Karam, and
P H Forsham
January 1993,
Acta veterinaria Scandinavica. Supplementum,
M Lorenzi, and
J E Gerich, and
J H Karam, and
P H Forsham
January 1986,
Comptes rendus des seances de la Societe de biologie et de ses filiales,
M Lorenzi, and
J E Gerich, and
J H Karam, and
P H Forsham
October 1979,
Experientia,
M Lorenzi, and
J E Gerich, and
J H Karam, and
P H Forsham
November 1972,
Acta medica Scandinavica,
M Lorenzi, and
J E Gerich, and
J H Karam, and
P H Forsham
April 1971,
British medical journal,
